Rockefeller Capital Management’s Vir Biotechnology VIR Stock Holding History

Rockefeller Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$400K	Sell	39,259 -64	-0.2%	-$609	﹤0.01%	2210
2026 Q1	$352K	Buy	39,323 +9,454	+32%	+$75.3K	﹤0.01%	2168
2025 Q4	$180K	Buy	29,869 +19,472	+187%	+$116K	﹤0.01%	2429
2025 Q3	$59.4K	Buy	+10,397	New	+$53.2K	﹤0.01%	2822
2023 Q1	–	Sell	-4,726	Closed	-$119K	–	3826
2022 Q4	$119K	Sell	4,726 -47	-1%	-$1.15K	﹤0.01%	1941
2022 Q3	$92K	Buy	4,773 +4,652	+3,845%	+$118K	﹤0.01%	2035
2022 Q2	$3K	Buy	+121	New	+$2.83K	﹤0.01%	3708
2021 Q3	–	Sell	-13,832	Closed	-$653K	–	3856
2021 Q2	$653K	Hold	13,832	–	–	﹤0.01%	1090
2021 Q1	$709K	Buy	13,832 +9,001	+186%	+$485K	﹤0.01%	908
2020 Q4	$129K	Buy	+4,831	New	+$157K	﹤0.01%	1345

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Rockefeller Capital Management's VIR Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Vir Biotechnology (VIR) stake by 0.16% in Q2 2026, selling an estimated $609 and leaving 39,259 shares worth $400K. The position accounts for ﹤0.01% of the portfolio, ranked #2210.

Rockefeller Capital Management first reported a position in VIR in Q4 2020 and has held it in 10 quarters since. The position peaked at $709K in Q1 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Rockefeller Capital Management held 39,259 shares of Vir Biotechnology worth $400K as of Q2 2026.
Rockefeller Capital Management sold 64 Vir Biotechnology shares in Q2 2026, an estimated $609.
Vir Biotechnology made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #2210 holding.
Rockefeller Capital Management first reported a position in Vir Biotechnology in Q4 2020 and has held it in 10 quarters since.
Rockefeller Capital Management's Vir Biotechnology position peaked at $709K in Q1 2021.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.